Market Overview

UPDATE: JP Morgan Downgrades GlaxoSmithKline to Underweight; Investments Risk Earnings

Share:
Related GSK
EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, Ready For Phase 1 Study By Q4
Benzinga's M&A Chatter for Thursday January 28, 2015
Is GlaxoSmithKline's 6% Dividend Sustainable? (Seeking Alpha)

JP Morgan reduced its rating on GlaxoSmithKline (NYSE: GSK) from Neutral to Underweight as the company's upcoming investment phase puts 2013 earnings at risk.

JP Morgan commented, "With material risk to 2013 earnings, no imminent positive catalysts, and almost no upside to our new PT, we downgrade to Underweight. GSK is entering an investment phase. After reassessing the investment required to execute on the pipeline, already taken for granted by consensus, we now expect Operating margins to contract, rather than expand in 2013, and we now forecast a 2013 Operating margin 200bps below consensus. We see earnings risk in 2013, with material Operating profit and earnings growth unlikely for at least a year further out than is currently forecast by consensus (which expects topline growth and margin expansion in 2013)."

GlaxoSmithKline closed at $46.07 on Tuesday.

Latest Ratings for GSK

DateFirmActionFromTo
Jan 2016Bryan GarnierUpgradesNeutralBuy
Oct 2015Credit SuisseUpgradesUnderperformNeutral
Oct 2015JP MorganUpgradesUnderweightNeutral

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (GSK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters